ALNEV fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Neovacs SA is a biotechnology company focused on therapeutic vaccines targeting the treatment of autoimmune diseases. The firm is developing a product portfolio using its Kinoid technology through self-antigens, which cause autoimmune or inflammatory diseases. Its product portfolio includes IFNa kinoid, IL-4/13 kinoid, and IgE kinoid. The company was founded by Daniel Zagury on April 16, 1993 and is headquartered in Paris, France.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
ALNEV does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company